KORU Medical Systems to Report Second Quarter 2024 Financial Results on August 7, 2024

Rhea-AI Summary

KORU Medical Systems (NASDAQ: KRMD), a leading medical technology company specializing in large volume subcutaneous infusion solutions, has announced its plans to report second quarter 2024 financial results on August 7, 2024. The company will host a conference call and webcast at 4:30 p.m. ET on the same day to discuss the results and provide a corporate update.

Interested parties can access the conference call by dialing (877)-407-0784 for U.S. or Canada participants, and (201)-689-8560 for international callers. A live and archived webcast will be available on the company's investor relations website for six months following the event.

MAHWAH, N.J.--(BUSINESS WIRE)-- KORU Medical Systems (NASDAQ: KRMD) (“KORU Medical” or the “Company”), a leading medical technology company focused on development, manufacturing, and commercialization of innovative and patient-centric large volume subcutaneous infusion solutions, today announced that the Company will report second quarter 2024 financial results on Wednesday, August 7, 2024. KORU Medical’s management will host a conference call and webcast at 4:30 p.m. ET that day to discuss the financial results and provide a corporate update.

Conference Call and Webcast Details

The conference call can be accessed by dialing (877)-407-0784 for participants in the U.S. or Canada and (201)-689-8560 for international callers. A live and archived webcast of the event can be accessed via the IR Calendar on the News/Events page of the Investors section of KORU Medical’s website at www.korumedical.com. The archived webcast will be available for six months.

About KORU Medical Systems

KORU Medical Systems develops, manufactures, and commercializes innovative and patient-centric large volume subcutaneous infusion solutions that improve quality of life for patients around the world. The FREEDOM Syringe Infusion System (the “Freedom System”) currently includes the FREEDOM60^® and FreedomEdge^® Syringe Infusion Drivers, Precision Flow Rate Tubing™ and HIgH-Flo Subcutaneous Safety Needle Sets™. The Freedom System, which received its first FDA clearance in 1994, is used for self-administration in the home by the patient and/or delivery in an ambulatory infusion center by a healthcare professional. Through its Novel Therapies business, KORU Medical provides products for use by biopharmaceutical companies in feasibility/clinical trials during the drug development process and, as needed, is capable of customizing the Freedom System for clinical and commercial use across multiple drug categories. For more information, please visit www.korumedical.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240717571985/en/

Investor Contact:

Greg Chodaczek

347-620-7010

investor@korumedical.com

Source: KORU Medical Systems

FAQ

When will KORU Medical Systems (KRMD) report its Q2 2024 financial results?

KORU Medical Systems (KRMD) will report its second quarter 2024 financial results on Wednesday, August 7, 2024.

What time is KORU Medical Systems' (KRMD) Q2 2024 earnings call scheduled for?

KORU Medical Systems' (KRMD) Q2 2024 earnings call is scheduled for 4:30 p.m. ET on August 7, 2024.

How can investors access KORU Medical Systems' (KRMD) Q2 2024 earnings call?

Investors can access KORU Medical Systems' (KRMD) Q2 2024 earnings call by dialing (877)-407-0784 for U.S. or Canada participants, or (201)-689-8560 for international callers. A live webcast will also be available on the company's investor relations website.

Where can I find the archived webcast of KORU Medical Systems' (KRMD) Q2 2024 earnings call?

The archived webcast of KORU Medical Systems' (KRMD) Q2 2024 earnings call will be available for six months on the News/Events page of the Investors section of the company's website at www.korumedical.com.